SREBF1 and neoplasm: In both in vitro and in vivo experiments, we demonstrated that the CREB3L2/HAT1/SREBP1 axis promotes tumor cell proliferation and metastasis by enhancing lipid metabolism, and targeting CREB3L2 can partially overcome lenvatinib resistance to augment therapeutic efficacy.